Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Céleste Lebbé"'
Autor:
Christoph Hoeller, Marie-Francoise Avril, Pietro Quaglino, François Aubin, Lars Bastholt, Takashi Inozume, Virginia Ferraresi, Michael B. Jameson, Kevin B. Kim, Oliver Bechter, Dirk Schadendorf, Kenji Yokota, Carmen Loquai, Maria-Jose Passos, Inge Marie Svane, Michele Maio, Catherine Barrow, Frank Meiss, Nageatte Ibrahim, Andrzej Mackiewicz, Phillip Parente, Tatsuya Takenouchi, Caroline Dutriaux, Piotr Rutkowski, Alfonsus J M van den Eertwegh, Paola Queirolo, Catriona M. McNeil, Peter Mohr, Felix Kiecker, Susana Puig, Friedegund Meier, Lutz Kretschmer, Alexander C.J. van Akkooi, Alex Menzies, Timothy Crook, Christian U. Blank, Suzana Matkovic, Michael C. Brown, Ragini R. Kudchadkar, Max Levin, Rüdiger Hein, Tanja Skytta, Gerald P. Linette, Clemens Krepler, Adnan Khattak, Ernest Marshall, Joseph Kerger, Oddbjorn Straume, Laurent Mortier, Jochen Utikal, Micaela Hernberg, James Larkin, Yoshio Kiyohara, Mario Mandalà, Henrik Schmidt, Daniil Stroyakovskiy, Pablo Luis Ortiz Romero, Naoya Yamazaki, John Walker, Anna Maria Di Giacomo, Lionel Geoffrois, Jean-Philippe Lacour, Caroline Robert, Vincent Descamps, Shahneen Sandhu, Gil Bar-Sela, Paul C. Nathan, Marcin Dzienis, Ralf Gutzmer, Claus Garbe, Andrey Meshcheryakov, Patrick Combemale, Martin Fehr, Guzel Mukhametshina, Helena Kapiteijn, Geke A. P. Hospers, Jun Aoi, Andrew Haydon, Rutger H. T. Koornstra, Marie-Thérèse Leccia, Sigrun Hallmeyer, Pier Francesco Ferrucci, Jean-Jacques Grob, Leonel Hernandez-Aya, Jan-Christoph Simon, Vanna Chiarion Sileni, Alain Algazi, Lidija Sekulovic, Sandrine Marreaud, Bernard Fitzharris, Jacob Schachter, Xinni Song, Wolf-Henning Boehncke, Rahima Jamal, Paul Lorigan, Maureen J.B. Aarts, Reinhard Dummer, Mike McCrystal, César Martins, Reiner Hofmann-Wellenhof, Alexander M.M. Eggermont, Carola Berking, Elaine Dunwoodie, Bernard Guillot, Michal Kicinski, Philippe Saiag, Céleste Lebbé, Thierry Lesimple, Stefan Suciu, Michal Lotem, Paula Ferreira, Mohammed M. Milhem, Laurent Machet, Patrick Terheyden, Anna Katharina Winge-Main, Peter Hersey, Jean-Francois Baurain, Axel Hauschild, Stéphane Dalle, Jean-Philippe Arnault, Paolo A. Ascierto, Gerard Groenewegen, Florent Grange, Georgina V. Long, Victoria Atkinson, Philippa Corrie, Matteo S. Carlino, Thomas Jouary, Daniel Hendler, Richard Casasola, Ashita Waterston, Jessica C. Hassel
Publikováno v:
EORTC Melanoma Group 2021, ' Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial ', The Lancet Oncology, vol. 22, no. 5, pp. 643-654 . https://doi.org/10.1016/S1470-2045(21)00065-6
Lancet Oncology, 22, 643-654
Lancet Oncology, 22, 5, pp. 643-654
Lancet Oncology
Lancet Oncology, 2021, 22 (5), pp.643-654. ⟨10.1016/S1470-2045(21)00065-6⟩
The Lancet Oncology, 22(5), 643-654. Lancet Publishing Group
Lancet Oncology, 22, 643-654
Lancet Oncology, 22, 5, pp. 643-654
Lancet Oncology
Lancet Oncology, 2021, 22 (5), pp.643-654. ⟨10.1016/S1470-2045(21)00065-6⟩
The Lancet Oncology, 22(5), 643-654. Lancet Publishing Group
Background: The European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients with resected high-risk stage III melanoma. At 15-month median follow-up, pembrolizumab improv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca46af8de45fdf5ffd9d70f717e94208
https://research.vumc.nl/en/publications/8aae177c-dfa8-4325-b8c2-e7b1d7339027
https://research.vumc.nl/en/publications/8aae177c-dfa8-4325-b8c2-e7b1d7339027
Autor:
Céleste Lebbé, Merrick I. Ross, Axel Hauschild, Theodore F. Logan, Robert H.I. Andtbacka, John A. Glaspy, Philip Friedlander, Claus Garbe, Jason Chesney, Omid Hamid, Howard L. Kaufman, Parminder Singh, Jenny J. Kim, Frances A. Collichio, Jennifer Gansert, Mohammed M. Milhem, Lisa Chen, Igor Puzanov
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 36, iss 17
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II study. To our knowledge, this was the first randomized trial to evaluate addition of an oncolyti
Autor:
Alexander M.M. Eggermont, Stefan Suciu, Céleste Lebbé, Vanna Chiarion-Sileni, Corneel Coens, Michael Smylie, Alessandro Testori, Omid Hamid, Srividya Kotapati, Andrew Bottomley, Jon M. Richards, Jeffrey S. Weber, Reinhard Dummer, Jean-Jacques Grob, Virginia Ferraresi, Michele Maio, Veerle de Pril, Caroline Robert, Henrik Schmidt, Paolo A. Ascierto, Jedd D. Wolchok
Publikováno v:
Coens, C, Suciu, S, Chiarion-Sileni, V, Grob, J-J, Dummer, R, Wolchok, J D, Schmidt, H, Hamid, O, Robert, C, Ascierto, P A, Richards, J M, Lebbé, C, Ferraresi, V, Smylie, M, Weber, J S, Maio, M, Bottomley, A, Kotapati, S, de Pril, V, Testori, A & Eggermont, A M M 2017, ' Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial ', Lancet Oncology, vol. 18, no. 3, pp. 393-403 . https://doi.org/10.1016/S1470-2045(17)30015-3
BACKGROUND:The EORTC 18071 phase 3 trial compared adjuvant ipilimumab with placebo in patients with stage III melanoma. The primary endpoint, recurrence-free survival, was significantly longer in the ipilimumab group than in the placebo group. Invest
Autor:
Mazhar Ajaz, Laurent Mortier, Inge Marie Svane, Ivan Marquez-Rodas, Thomas Eigentler, Jennifer Lord-Bessen, Paolo A. Ascierto, Elena Grigoryeva, Dirk Schadendorf, Caroline Robert, Linda Rollin, Jacopo Pigozzo, Nicolas Meyer, Michael Smylie, Rene Gonzalez, Alexander M. Menzies, Piotr Rutkowski, Céleste Lebbé, Abdel Saci
Publikováno v:
Journal of Clinical Oncology
Lebbé, C, Meyer, N, Mortier, L, Marquez-Rodas, I, Robert, C, Rutkowski, P, Menzies, A M, Eigentler, T, Ascierto, P A, Smylie, M, Schadendorf, D, Ajaz, M, Svane, I M, Gonzalez, R, Rollin, L, Lord-Bessen, J, Saci, A, Grigoryeva, E & Pigozzo, J 2019, ' Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma : Results From the Phase IIIb/IV CheckMate 511 Trial ', Journal of Clinical Oncology, vol. 37, no. 11, pp. 867-875 . https://doi.org/10.1200/JCO.18.01998
Lebbé, C, Meyer, N, Mortier, L, Marquez-Rodas, I, Robert, C, Rutkowski, P, Menzies, A M, Eigentler, T, Ascierto, P A, Smylie, M, Schadendorf, D, Ajaz, M, Svane, I M, Gonzalez, R, Rollin, L, Lord-Bessen, J, Saci, A, Grigoryeva, E & Pigozzo, J 2019, ' Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma : Results From the Phase IIIb/IV CheckMate 511 Trial ', Journal of Clinical Oncology, vol. 37, no. 11, pp. 867-875 . https://doi.org/10.1200/JCO.18.01998
PURPOSE Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg (NIVO1+IPI3) is approved for first-line treatment of patients with advanced melanoma in several countries. We conducted a phase IIIb/IV study (CheckMate 511) to determine if nivolumab 3 mg/kg plus ipi
Autor:
A. Dupont, Nicole Basset-Seguin, R. Lhote, Jérôme Lambert, Barouyr Baroudjian, M. Chapalain, Céleste Lebbé, Martine Bagot
Publikováno v:
Journal of the European Academy of Dermatology and Venereology : JEADVReferences. 34(6)
Background The prevalence and incidence of cutaneous squamous cell carcinoma (cSCC) are increasing due to the ageing of the population and sun exposure. Advanced cSCC forms (locally advanced and/or locoregional metastatic and/or distant metastatic) a
Autor:
Howard L. Kaufman, Meliessa Hennessy, Jeffery S. Russell, Sandra P. D'Angelo, Marcis Bajars, Guilherme Rabinowits, Céleste Lebbé, Jean-Jacques Grob, Bartosz Chmielowski, Patrick Terheyden, Thilo Gambichler, Felix Kiecker, Isabella Zwiener
Publikováno v:
JAMA oncology. 4(9)
Importance Merkel cell carcinoma (MCC) is an aggressive skin cancer that is associated with poor survival outcomes in patients with distant metastatic disease. Results of part A of the JAVELIN Merkel 200 trial (avelumab in patients with Merkel cell c
Autor:
Alexander M.M. Eggermont, Stefan Suciu, Jessica C. Hassel, Saad Tahir, Michael Smylie, Virginia Ferraresi, F. Stephen Hodi, Jon M. Richards, Jean-Jacques Grob, Gaetan de Schaetzen, Michele Maio, Lars Bastholt, Céleste Lebbé, Luc Thomas, Jeffrey S. Weber, Corina Taitt, Jedd D. Wolchok, Alessandro Testori, Omid Hamid, Reinhard Dummer, Vanna Chiarion-Sileni, Veerle de Pril, Caroline Robert, Laurent Mortier, Axel Hauschild, Paolo A. Ascierto, Henrik Schmidt
Publikováno v:
Eggermont, A M M, Chiarion-Sileni, V, Grob, J-J, Dummer, R, Wolchok, J D, Schmidt, H, Hamid, O, Robert, C, Ascierto, P A, Richards, J M, Lebbé, C, Ferraresi, V, Smylie, M, Weber, J S, Maio, M, Bastholt, L, Mortier, L, Thomas, L, Tahir, S, Hauschild, A, Hassel, J C, Hodi, F S, Taitt, C, de Pril, V, de Schaetzen, G, Suciu, S & Testori, A 2016, ' Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy ', The New England Journal of Medicine, vol. 375, no. 19, pp. 1845-1855 . https://doi.org/10.1056/NEJMoa1611299
BACKGROUND: On the basis of data from a phase 2 trial that compared the checkpoint inhibitor ipilimumab at doses of 0.3 mg, 3 mg, and 10 mg per kilogram of body weight in patients with advanced melanoma, this phase 3 trial evaluated ipilimumab at a d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80e78ee5b514ba66d939ec946d41104c
https://pure.au.dk/portal/da/publications/prolonged-survival-in-stage-iii-melanoma-with-ipilimumab-adjuvant-therapy(0df58c2a-4640-459d-be0c-75fa394c3bcb).html
https://pure.au.dk/portal/da/publications/prolonged-survival-in-stage-iii-melanoma-with-ipilimumab-adjuvant-therapy(0df58c2a-4640-459d-be0c-75fa394c3bcb).html
Publikováno v:
Current medical research and opinion. 29(10)
Melanoma is associated with high mortality and poor response to standard chemotherapy. In order to benchmark benefits of recently introduced treatments, outcome with standard chemotherapy in everyday practice should be documented.To document treatmen
Autor:
Olivier Verola, A. Archimbaud, Marie-Elisabeth Toubert, Delphine Kerob, François Plassa, Marc Revol, Marie-Pierre Podgorniak, Raphaël Porcher, Michel Baccard, Nicole Basset-Seguin, L. Ollivaud, Jean-Marie Servant, Samia Mourah, Noël E. C. Schartz, Dominique Vitoux, Céleste Lebbé
Publikováno v:
Archives of dermatology. 145(10)
To evaluate the prognostic value of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes (SLNs) with melanoma micrometastases.Prognostic study of an inception cohort.Academic research. Patients Between July 1, 1999